 treatment testicular cancer new improv model testicular cancer model curabl neoplasm prior advent cisplatin combin chemotherapi standard chemotherapi dactinomycin combin chlorambucil methotrex germ cell tumor chemosensit regimen object respons rate complet remiss rate cure rate initi cisplatin vinblastin bleomycin pvb chemotherapi patient dissemin germ cell tumor complet remiss CR addit disease-fre post-pvb resect teratoma carcinoma twenty-seven patient disease-fre minim follow-up year cisplatin-bas chemotherapi one-log increas cure rate dactinomycin subsequ phase iii studi vinblastin dosag mg/kg mg/kg reduct toxic decrement therapeut efficaci third-gener pvb studi optim cure rate week induct therapi pvb long-term mainten therapi vinblastin unnecessari salvag therapi cisplatin etoposid patient pvb patient regimen first time adult solid tumor second-lin regimen studi third-lin therapi cisplatin ifosfamid combin chemotherapi refractori set patient curabl cisplatin bleomycin pvb first-lin chemotherapi signific reduct neuromuscular toxic arm patient disease-fre pvb patient dissemin germ cell tumor addit curabl salvag chemotherapi cure rate adult malign